Hansa Biopharma Reports Fourth Quarter and Full Year 2024
-
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
Hansa Biopharma: Ends 2024 on a softer note
Research Note 2025-02-06 08:15
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European guidelines.
https://www.redeye.se/research/1072967/hansa-biopharma-ends-2024-on-a-softer-note
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind